Aytu Biopharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AYTU Nasdaq 2834 http://aytubio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aytu Biopharma Inc

Aytu BioPharma Inc. (AYTU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Mar 6th, 2023 2:55 pm
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2023 Earnings Call Transcript - Feb 23rd, 2023 9:33 pm
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023 - Feb 21st, 2023 9:10 pm
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023 - Feb 21st, 2023 8:00 pm
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results - Feb 14th, 2023 1:00 pm
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023 - Feb 7th, 2023 1:00 pm
Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Expected To Breakeven In The Near Future - Feb 6th, 2023 3:57 pm
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance - Jan 25th, 2023 1:00 pm
Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31 - Jan 24th, 2023 1:00 pm
Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients - Jan 10th, 2023 1:00 pm
Aytu BioPharma Announces 1-for-20 Reverse Stock Split - Jan 5th, 2023 9:01 pm
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2023 Earnings Call Transcript - Dec 29th, 2022 11:01 am
Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect - Nov 30th, 2022 1:00 pm
Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule - Nov 22nd, 2022 9:05 pm
US$5.50: That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After Its Latest Results - Nov 17th, 2022 1:58 pm
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row - Nov 17th, 2022 1:00 pm
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso - Nov 16th, 2022 1:00 pm
Aytu BioPharma First Quarter 2023 Earnings: Beats Expectations - Nov 16th, 2022 10:59 am
Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023 - Nov 14th, 2022 9:05 pm
Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022 - Nov 7th, 2022 9:01 pm